Stoke Therapeutics, Inc. (STOK) Stock Analysis: Impressive Revenue Growth and Promising Upside
Stoke Therapeutics, Inc. (STOK) shows promising growth with a market capitalization of $1.96 billion and a robust revenue increase of 117.20%. Analysts are bullish, projecting an average target price of $41.89, indicating a potential upside of 21.88%. The company's innovative TANGO platform is advancing treatments for genetic diseases, with lead candidates STK-002 and Zorevunersen (STK-001) in various stages of clinical development.
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics, Inc. announced that it granted stock options to five new employees to purchase an aggregate of 22,950 shares of common stock. These grants, effective February 17, 2026, serve as a material inducement for their employment under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $31.09 per share, consistent with the closing price on the grant date, and vest over a four-year period.
Liquidity Mapping Around (STOK) Price Events
This article provides an AI-driven liquidity mapping and sentiment analysis for Stoke Therapeutics Inc. (NASDAQ: STOK), characterizing its near-term sentiment as neutral amid mid and long-term strength. It outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also highlights key support and resistance levels across different time horizons, alongside a notable risk-reward short setup.
Stoke Therapeutics spotlights durable Dravet gains, Phase 3 timeline, and new ADOA program at summit
Stoke Therapeutics highlighted long-term, durable seizure reductions and cognitive improvements in its Dravet syndrome program, with Phase 3 enrollment expected to conclude in Q2 2026 and pivotal data by mid-2027. The company also announced the initiation of a new Phase I/II program for autosomal dominant optic atrophy (ADOA), with first patient dosed. Stoke reported a strong financial position, ending 2025 with $400 million in cash, providing runway into 2028.
Stoke Therapeutics spotlights durable Dravet gains, Phase 3 timeline, and new ADOA program at summit
Stoke Therapeutics presented long-term data for its Dravet syndrome program, showing durable seizure reductions and cognitive improvements, and outlined the design of its ongoing EMPEROR Phase 3 trial. The company also announced the initiation of a new Phase I/II dose-escalation program for autosomal dominant optic atrophy (ADOA). Stoke Therapeutics ended 2025 with $400 million in cash, providing a runway into 2028.
A Look At Stoke Therapeutics (STOK) Valuation After Strong One Year Share Price Momentum
Stoke Therapeutics (STOK) has experienced significant share price momentum, with a 214% return over the past year. Despite this, the stock is currently seen as modestly undervalued by analysts, with a fair value of $34.25 compared to its trading price of $32.22, based on future earnings and revenue projections. However, its current P/E ratio of 45.4x is higher than peers and the industry average, suggesting potential valuation risk if market sentiment shifts.
Stoke Therapeutics announces first patient dosed in Phase 1 study of STK-002
Stoke Therapeutics has announced that the first patient has been dosed in its Phase 1 study for STK-002. This compound is being developed for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach to restore protein levels.
Stoke Therapeutics Announces First Patient Dosed In Phase 1 Study Of Stk-002
Stoke Therapeutics (STOK) has announced that the first patient has been dosed in its Phase 1 study of STK-002. This news was reported by Reuters and is considered a significant development for the company's research and product pipeline. The article indicates this is a key step in their clinical development process.
Stoke Therapeutics announced that the dose-escalation phase for the first four cohorts of its research project will continue into 2026 and early 2027.
Stoke Therapeutics has announced that the dose-escalation phase for the initial four cohorts of its research project will extend into 2026 and early 2027. This extension is contingent on the ongoing evaluation of the drug's safety and tolerability. The company stressed that the dose escalation plan will be implemented gradually, prioritizing patient safety above all else.
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)
Stoke Therapeutics has announced that the first patient has been dosed in its Phase 1 OSPREY study of STK-002, an investigational medicine for Autosomal Dominant Optic Atrophy (ADOA). ADOA is a rare genetic disease leading to progressive and irreversible vision loss, with no approved treatments currently available. STK-002 aims to restore OPA1 protein expression, addressing the root cause of the disease and potentially restoring vision.
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Stoke Therapeutics (NASDAQ:STOK) has received a consensus "Moderate Buy" rating from eleven brokerages, with an average 12-month price target of $39.18. The company's stock opened at $31.99, boasts a market cap of $1.83 billion, and has seen notable institutional investment increases despite insider sales. Stoke Therapeutics is a clinical-stage biopharmaceutical company developing genetic medicines for rare neuromuscular and neurological disorders.
Guggenheim Upgrades Stoke Therapeutics (NASDAQ:STOK) to "Strong-Buy"
Guggenheim has upgraded Stoke Therapeutics (NASDAQ:STOK) to a "strong-buy" rating, with a consensus target price of $39.18 from MarketBeat. Despite analyst optimism, company insiders have been net sellers, with 98,774 shares sold in the last 90 days. Stoke Therapeutics is a clinical-stage biopharmaceutical company developing genetic medicines for rare neuromuscular and neurological disorders, with its lead program STK-001 targeting Dravet syndrome.
Why (STOK) Price Action Is Critical for Tactical Trading
This article analyzes Stoke Therapeutics Inc. (NASDAQ: STOK), highlighting strong positive sentiment across all trading horizons. It details an exceptional risk-reward setup targeting a 19.1% gain with minimal risk and outlines three distinct AI-generated trading strategies—position trading, momentum breakout, and risk hedging—with specific entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal information for support and resistance levels.
Stoke Therapeutics stock jumps after Guggenheim initiates with Buy rating
Stoke Therapeutics Inc. (NASDAQ:STOK) saw its stock jump 5.7% after Guggenheim initiated coverage with a Buy rating and a $60.00 price target. The positive outlook is based on the potential of the company's lead asset, zorevunersen, for treating Dravet syndrome, which is seen as a potentially disease-modifying treatment. The analyst highlighted zorevunersen's benefits beyond seizure reduction and the de-risked nature of its ongoing Phase III trial.
Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Stoke Therapeutics, Inc., a biotechnology company specializing in RNA medicine, announced that CEO Ian F. Smith will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026. The company is developing zorevunersen, a lead investigational medicine for Dravet syndrome, which is currently in a Phase 3 study and has received Breakthrough Therapy Designation from the FDA. A live audio webcast and archived replay will be available on Stoke’s investor relations website.
Stoke Therapeutics, Inc. (STOK) Investor Outlook: A Promising 27.53% Upside Potential In Biotech
Stoke Therapeutics, Inc. (NASDAQ: STOK), a biotech firm focused on genetic diseases with a $1.77 billion market cap, shows significant growth potential. The company's innovative TANGO approach and lead candidates for conditions like Dravet syndrome, along with collaborations with Biogen and Acadia Pharmaceuticals, position it for future success. Analysts are bullish, with an average target price suggesting a 27.53% upside, despite the company currently not generating profits, which is typical for early-stage biotechs.
A Look At Stoke Therapeutics (STOK) Valuation As New Waltham Headquarters Signals Growth Plans
Stoke Therapeutics (STOK) has leased a new 98,500 square foot headquarters and lab in Waltham, Massachusetts, signaling growth plans and potential commercialization. The company's shares are currently trading around $31.07, suggesting a 9.3% undervaluation compared to a fair value of $34.25, despite a strong 182.71% one-year return. The valuation narrative highlights future revenue expansion but also notes risks like potential trial failures and pricing pushback.
Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA
Anchor Line Partners and Northwood Investors have secured a long-term lease for 98,500 square feet at 245 Fifth Avenue in Waltham, MA, for Stoke Therapeutics. This new headquarters will support Stoke's growth, including commercializing zorevunersen for Dravet syndrome and expanding research efforts. The lease highlights the resilience of the Greater Boston life sciences market and Waltham's emergence as a key suburban biotech hub.
Huge Waltham lab lease fuels work on potential Dravet syndrome drug
Stoke Therapeutics (NASDAQ: STOK) has signed a long-term lease for a 98,500 square-foot headquarters at 245 Fifth Avenue in Waltham, MA, planning occupancy after its Bedford lease ends in late 2026. This move supports the company's growth as it prepares to commercialize zorevunersen, a potential drug for Dravet syndrome, and expand its RNA platform research. The lease is noted as one of the largest Greater Boston life sciences transactions in the past year, highlighting Waltham's strong position in the biotech industry.
Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA
Anchor Line Partners and Northwood Investors have secured a long-term lease for 98,500 square feet with Stoke Therapeutics in Waltham, Massachusetts. This new headquarters will support Stoke's growth, including commercialization efforts for zorevunersen, a potential disease-modifying medicine for Dravet syndrome, and expansion of their research. The lease is one of the largest in the Greater Boston life sciences market over the past year, highlighting Waltham's continued strength as a biotech hub.
Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA
Anchor Line Partners and Northwood Investors have secured a 98,500 square-foot long-term lease for Stoke Therapeutics in Waltham, MA, facilitating the biotechnology company's growth as it prepares to commercialize a medicine for Dravet syndrome and expand research. This move to 245 Fifth Avenue aligns with Stoke's evolving needs for innovation and collaboration. The lease highlights the continued strength of the Greater Boston life sciences market and Waltham's emergence as a key hub.
Understanding Momentum Shifts in (STOK)
This article analyzes momentum shifts for Stoke Therapeutics Inc. (NASDAQ: STOK), identifying a positive near-term sentiment within a long-term strong context, despite a mid-term weak bias. It highlights an exceptional risk-reward setup targeting a 21.0% gain. The piece also details three AI-generated trading strategies tailored for different risk profiles, along with multi-timeframe signal analysis.
Stoke Therapeutics Expands with New Long-Term Waltham Headquarters
Stoke Therapeutics (STOK) has signed a 12-year lease for a new 98,500 square-foot corporate headquarters and laboratory in Waltham, Massachusetts, involving an estimated $85.5 million in base rent. This expansion reinforces the company's commitment to scaling its R&D operations and supporting future growth. TipRanks' AI Analyst, Spark, rates STOK as Neutral, citing improving financials and technical uptrends tempered by expensive valuation and cash flow volatility.
How Accelerated EMPEROR Enrollment and Expedited FDA Talks At Stoke Therapeutics (STOK) Have Changed Its Investment Story
Stoke Therapeutics announced accelerated enrollment for its Phase 3 EMPEROR study of zorevunersen for Dravet syndrome, with data expected in mid-2027 and potential for a rolling NDA due to Breakthrough Therapy Designation. This update positively impacts the company's investment narrative by bringing a key catalyst into sharper focus, despite concentrating risk on a single late-stage asset. The investment thesis hinges on zorevunersen's commercial success, supported by ongoing FDA dialogue for expedited pathways in a disease with no approved disease-modifying treatments.
Stoke Therapeutics (STOK) Stock Analysis: Unveiling Growth Potential with a 23.54% Upside
Stoke Therapeutics (STOK) is attracting investor attention in the biotechnology sector due to its innovative TANGO technology for genetic disease treatments. The company, with a market capitalization of $1.72 billion, has a bullish average target price of $37.13, indicating a potential upside of 23.54%, supported by unanimous "buy" ratings from analysts. Despite being an early-stage biotech firm with a negative forward P/E, its robust revenue growth and strategic collaborations position it as a compelling, high-risk, high-reward investment opportunity.
Stoke Therapeutics (STOK) Valuation Check As Phase 3 Dravet Study Advances And FDA Discussions Progress
Stoke Therapeutics (STOK) recently provided an update on its Phase 3 EMPEROR study for zorevunersen in Dravet syndrome, noting faster enrollment and clearer data timelines, alongside ongoing FDA discussions for expedited review. Despite a strong 194.41% return over the past year, its P/E ratio of 41.5x appears overvalued compared to the biotech industry average, although a Discounted Cash Flow analysis suggests it might be significantly undervalued at $29.50. Investors are encouraged to consider these mixed signals, weighing potential risks and opportunities related to trial outcomes and underlying assumptions.
Stoke Therapeutics (STOK) Valuation Check As Phase 3 Dravet Study Advances And FDA Discussions Progress
Stoke Therapeutics (STOK) announced faster enrollment and a clearer data timeline for its Phase 3 EMPEROR study of zorevunersen in Dravet syndrome, alongside ongoing FDA discussions for expedited review. Despite a strong 194.41% one-year return, the stock's 41.5x P/E ratio is considered overvalued compared to the biotech industry average, though a DCF model suggests it might be significantly undervalued. Investors are encouraged to assess the risks and potential and use various valuation models to form their own narrative.
Stoke Therapeutics, Inc. $STOK is Skorpios Trust's Largest Position
Skorpios Trust significantly reduced its stake in Stoke Therapeutics (STOK) by 30.7%, selling 1 million shares, yet the biotech company still constitutes 99.7% of the trust's holdings, valued at $53.02 million. Recent insider selling has also been noted, with executives offloading shares worth over $3 million. Despite these reductions, analyst sentiment remains generally positive, with a "Moderate Buy" rating and an average price target of $37.10.
Faster-than-expected enrollment seen in trial testing zorevunersen for Dravet
Enrollment in the Phase 3 EMPEROR clinical trial for zorevunersen, a Dravet syndrome treatment, is progressing faster than anticipated and is expected to complete by Q2 2026. This accelerated timeline could lead to a new drug application submission to the FDA in the first half of 2027. Zorevunersen, developed by Stoke Therapeutics in collaboration with Biogen, previously received breakthrough therapy designation and aims to reduce seizure frequency and improve overall clinical status in patients.
Biotech Stoke Therapeutics gives new hires 74,020 stock options each
Stoke Therapeutics announced the grant of 74,020 stock options to nine new employees as an inducement to their employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $29.28 per share, matching the closing price on January 15, 2026, and will vest over a four-year period. Stoke Therapeutics is a biotechnology company focused on RNA medicine, with a lead investigative medicine, zorevunersen, for Dravet syndrome.
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics, Inc. announced that it granted stock options to nine new employees on January 15, 2026, to induce their employment. These options cover an aggregate of 74,020 shares of common stock, with an exercise price matching the closing price of $29.28 per share on that date. The stock options will vest over a four-year period, in accordance with Nasdaq Listing Rule 5635(c)(4).
Stoke Therapeutics (STOK) Is Down 13.1% After Accelerating EMPEROR Trial Timeline And FDA Talks - Has The Bull Case Changed?
Stoke Therapeutics (STOK) shares dropped 13.1% after the company announced accelerated timelines for its Phase 3 EMPEROR trial of zorevunersen for Dravet syndrome, aiming for a mid-2027 data readout and rolling NDA submission. While the acceleration highlights strong patient identification and ongoing FDA discussions for expedited regulatory pathways, the stock's decline indicates investor uncertainty regarding the single-asset, high-stakes bet and potential for further downside despite the positive clinical developments. The article emphasizes that investors must believe in zorevunersen's success, with key milestones now in clearer focus and ongoing regulatory dialogue under Breakthrough Therapy Designation.
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Moderate Buy" by Analysts
Analysts have issued a consensus "Moderate Buy" recommendation for Stoke Therapeutics, Inc. (NASDAQ:STOK), with an average one-year price target of $37.10, and several firms recently raised their targets. Despite significant insider selling over the last 90 days, institutional investors have increased their stakes. The company recently reported an EPS miss but a revenue beat, with a market cap of $1.67 billion.
Is It Too Late To Revisit Stoke Therapeutics (STOK) After A 226% One-Year Surge?
Stoke Therapeutics (STOK) has experienced significant volatility, with a 226.3% return over the last year but recent short-term declines. A Discounted Cash Flow (DCF) analysis suggests the stock is heavily undervalued at approximately $30.97 per share, with an intrinsic value of about $251.32. However, its Price-to-Earnings (P/E) ratio of 43.60x is higher than the industry average and its calculated "Fair Ratio" of 22.12x, indicating it might be overvalued based on earnings.
STOK: Phase III for Dravet therapy nears full enrollment, with durable efficacy and regulatory momentum
Stoke Therapeutics (STOK) is nearing full enrollment in its Phase III trial for zorevunersen, a Dravet syndrome therapy, with completion expected in Q2 2026 and potential approval by Q4 2027. Four-year data reveal sustained seizure reduction and neurocognitive benefits. The company believes its robust pipeline and financial standing will support future growth.
A Look At Stoke Therapeutics (STOK) Valuation After Accelerated Phase 3 Timeline For Dravet Therapy
Stoke Therapeutics (STOK) has garnered attention due to accelerated timelines for its EMPEROR Phase 3 study of zorevunersen, targeting a mid-2027 data readout. Despite recent short-term share price fluctuations, the stock has shown significant long-term momentum. The article questions whether the current P/E ratio of 41.4x is justified, noting it's higher than industry averages and the estimated fair P/E, though a Discounted Cash Flow model suggests a much higher fair value.
Stoke Therapeutics (NASDAQ: STOK) sees cash runway into 2028 operations
Stoke Therapeutics (NASDAQ: STOK) announced an update via an 8-K filing regarding its financial position and the Phase 3 EMPEROR study of zorevunersen for Dravet syndrome. The company anticipates having approximately $391.7 million in cash, cash equivalents, and marketable securities as of December 31, 2025, which, combined with proceeds from its Biogen collaboration, is expected to fund operations into 2028. The filing also provides updated timelines for trial enrollment and data readout for the EMPEROR study.
Stoke Therapeutics stock maintains Overweight rating at Cantor Fitzgerald
Cantor Fitzgerald has reaffirmed its Overweight rating on Stoke Therapeutics (NASDAQ:STOK) due to ongoing discussions with the FDA regarding expedited regulatory pathways for its treatments. The company's shares have seen a 265% return over the past year, with analysts suggesting potential undervaluation. Stoke Therapeutics has also reported strong proforma cash reserves projected to fund operations into 2028, past key clinical trial readouts and potential approvals.
Stoke Therapeutics stock falls after delayed Phase 3 readout timeline
Stoke Therapeutics (NASDAQ:STOK) shares dropped significantly after the company provided updated timelines for its Phase 3 EMPEROR study of zorevunersen, a treatment for Dravet syndrome. Despite the company describing the new timelines as "accelerated," investors reacted negatively, perceiving it as a delay from prior expectations. Stoke Therapeutics, in partnership with Biogen, anticipates completing enrollment by Q2 2026 and reporting data in mid-2027, with intentions to submit a rolling NDA to the FDA in H1 2027.
Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $36.00 at Wedbush
Wedbush has raised its price target for Stoke Therapeutics (NASDAQ:STOK) to $36.00 from $32.00, maintaining an "outperform" rating, which implies a potential 9.59% upside. This adjustment comes despite the company missing EPS estimates but exceeding revenue expectations in its last earnings report. The consensus among analysts for Stoke Therapeutics is currently a "Moderate Buy" with an average target price of $37.10.
Stoke Therapeutics Says US FDA Seeks Additional Information for Zorevunersen in Dravet Syndrome; Shares Fall
Stoke Therapeutics announced that the US FDA has requested additional information regarding its investigational drug Zorevunersen for Dravet Syndrome, causing the company's shares to fall. The company previously reported plans to complete enrollment for a Phase 3 trial by Q2 2026 with data expected mid-2027, and has also presented positive long-term data for Zorevunersen in partnership with Biogen. The request for more information could potentially delay the drug's development or approval process.
Some Analysts Just Cut Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Estimates
Analysts have significantly revised down their revenue forecasts for Stoke Therapeutics, Inc. for 2026, now expecting a stressful 88% decline in sales. Despite this major downgrade and anticipation of a loss, the consensus price target for STOK rose, suggesting a disconnect between revenue sentiment and valuation expectations. The long-term earnings trajectory and insider ownership are highlighted as more critical factors for investors to consider.
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome
Stoke Therapeutics has accelerated timelines for its EMPEROR study of zorevunersen for Dravet syndrome, now expecting to complete enrollment of 150 patients in Q2 2026 and announce Phase 3 data by mid-2027. The company plans to initiate a rolling NDA submission in the first half of 2027, potentially delivering the drug to patients sooner than anticipated after productive, ongoing discussions with the FDA following its Breakthrough Therapy Designation. Stoke Therapeutics also confirmed approximately $391.7 million in cash, cash equivalents and marketable securities as of December 31, 2025, expected to fund operations into 2028.
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome
Stoke Therapeutics has announced accelerated timelines for its EMPEROR study of zorevunersen for Dravet syndrome, now expecting to complete enrollment of 150 patients in Q2 2026 and have Phase 3 data readout by mid-2027. This progress anticipates an earlier rolling NDA submission in the first half of 2027, potentially expediting patient access. Discussions with the FDA are ongoing regarding potential expedited regulatory pathways for zorevunersen, which has Breakthrough Therapy Designation.
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome
Stoke Therapeutics has announced accelerated timelines for its EMPEROR study of zorevunersen, a potential treatment for Dravet syndrome. The company now expects to complete enrollment of 150 patients in Q2 2026, with Phase 3 data readout in mid-2027, and plans to initiate a rolling NDA submission in the first half of 2027. Despite ongoing discussions with the FDA, no immediate changes to the development program were made, but Stoke continues to explore expedited regulatory pathways for zorevunersen.
Stoke Therapeutics Expects To Complete Enrollment Of 150 Patients In Q2 2026, With A Phase 3 Data Readout In Mid-2027 for Zorevunersen
Stoke Therapeutics (STOK) anticipates completing the enrollment of 150 patients for its Zorevunersen Phase 3 trial by Q2 2026. The company expects to announce the data readout for this trial in mid-2027. This news provides a timeline for key development milestones for Zorevunersen.
Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Stoke Therapeutics announced that CEO Ian F. Smith will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 7:30 p.m. ET. The presentation will be webcast live on the company's website, with a replay available for 30 days. Stoke Therapeutics is a biotechnology company focused on restoring protein expression using RNA medicine, with its lead investigational medicine, zorevunersen, in development for Dravet syndrome.
Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Stoke Therapeutics, Inc. announced that its Chief Executive Officer, Ian F. Smith, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The company is a biotechnology firm focused on RNA medicine, with its lead investigational medicine, zorevunersen, in development for Dravet syndrome. A live audio webcast of the presentation will be available on Stoke’s website, with a replay accessible for 30 days.
Cantor Fitzgerald reiterates Overweight rating on Stoke Therapeutics stock
Cantor Fitzgerald has reiterated its Overweight rating on Stoke Therapeutics (NASDAQ:STOK) due to the compelling clinical data from its zorevunersen program, which shows significant anti-seizure activity and potential disease-modifying effects. The firm projects zorevunersen could achieve over $1.5 billion in annual U.S. sales, significantly boosting Stoke's approximately $1.8 billion market capitalization. This positive outlook is supported by InvestingPro data highlighting STOK's impressive annual return of 169% and 1128% revenue growth in the last twelve months, alongside a low PEG ratio.
Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $35.00 at Chardan Capital
Chardan Capital has increased its price target for Stoke Therapeutics (NASDAQ:STOK) from $24.00 to $35.00, maintaining a "buy" rating, which aligns with a broader analyst consensus price target of $36.70. This increase follows Stoke Therapeutics reporting a revenue beat of $10.63 million against an expectation of $6.06 million, despite an EPS miss. Insider selling has occurred, but institutional investors have significantly increased their stakes in the company.
